Aquestive (AQST) CEO Daniel Barber Sells 25,000 Shares

What Happened Daniel Barber, President, CEO and Director of Aquestive Therapeutics, sold 25,000 common shares in an open-market transaction on August 17, 2026. The filing lists a per-share price of $4.29 and total proceeds of $107,168. A footnote to the Form 4 states the actual sale prices ranged from $4.24 to $4.35 with a weighted average price of $4.2867.

Key Details

• Transaction date: 2026-08-17 (reported on Form 4 filed 2026-08-18) — appears timely.
• Reported sale: 25,000 shares; reported price $4.29; total reported proceeds $107,168.
• Price range / weighted average (footnote): $4.24–$4.35; weighted average $4.2867. The filer offers to provide the number of shares sold at each price upon request.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Transaction code: S = sale (open-market/private sale as reported). No 10b5‑1 plan, tax withholding, or other special conditions were disclosed in the provided data.

Context This was a straight sale by the CEO and does not by itself indicate the company’s outlook. Retail investors often view purchases as stronger signals of insider conviction; sales can be routine (liquidity, diversification, tax planning) and should be interpreted with other filings and company fundamentals.